

## **PEDIATRIC CLINICAL PHARMACOLOGY SECTION REPORT. 2018 - 2019**

### **Executive Committee of the Paediatric Section for the term 2018-2022:**

Chairman: Facundo Garcia-Bournissen (Argentina/Canada)

Vice-Chairman: Karel Allegaert (Belgium)

Secretary: Zhiping Li (China)

Treasurer: Pierre Gressens (France)

Members: Steve Leeder (USA), Bruce Carleton (Canada)

The executive committee met during the 2019 European Society for Developmental, Perinatal and Pediatric Pharmacology (ESDPPP) meeting in Basel, Switzerland. The Committee also regularly communicates via email.

### **1) ACTIVITIES DURING 2018 – 2019**

- Due to the way the original bylaws of IUPHAR Pediatric Clinical Pharmacology were written, virtually all of the previous Executive Committee members had their terms expire in 2018. This meant that a completely new Executive Committee had to be put together, and this has taken time to organize given the limited number of pediatric clinical pharmacology available.
- The difficulty with the bylaws is being addressed and they will probably be changed to allow for terms to expire in a more staggered way that will allow less sudden transitions in the future.
- The new Committee has incorporated 5 new members (Dr Karel Allegaert as Vice-Chair, Dr Zhiping Li as Secretary, Dr Pierre Griessens as Treasurer, Dr Steve Leeder and Dr Bruce Carleton). Two positions remain to be filled, but the Committee is working on that at the moment.
- During the ESDPPP meeting, informal and formal exchanges took place among members of the committee that led to expansion of the members at the time, and exploring the interest of potential new members. These exchanges continue and we expect that they will conduce to new junior researchers joining the committee soon.
- The Members of the Executive Committee participated during the 2018 – 2019 period in a number of activities related to the mandate of the Pediatric Clinical Pharmacology Section, including collaborating in the organization of ESDPPP and being part of ESDPPP council (Dr Allegaert), providing advice to international organizations (e.g. DNDi, PAHO) on drug development for pediatric neglected diseases (Dr Garcia-Bournissen), delivering lectures on pediatric and neonatal pharmacology (Dr Allegaert, Dr Garcia Bournissen, Dr Carleton, Dr Leeder, Dr Li, Dr Greesens), organizing pediatric clinical pharmacology teaching activities for junior researchers, pediatric and pharmacy residents and students (Dr Li, Dr Allegaert, Dr Garcia Bournissen, Dr Carleton), participating in pediatric clinical pharmacology advocacy activities both at national and international level (Dr Allegaert, Dr Carleton, Dr Li, Dr Garcia Bournissen, Dr Leeder, Dr Greesens) and carrying out pediatric clinical pharmacology research (all members of the Executive Committee).
- The Executive Committee has held informal discussions exploring the possibility to re-launch dissemination activities that will help reach new potential members for the Section and kindle the interest on pediatric clinical pharmacology in junior researchers and clinicians. A previous model (GRiP-funded pediatric clinical pharmacology courses) that was successful and involved significant participation of former members of the Section may be a good example for future effort, especially in developing regions. Dr Li has mentioned that there

may be interest for such a course / seminar series in China. Previous efforts in Latin America and in India were quite successful and, if funding is secured, could be repeated.

## **2) ACTIVITIES PLANNED FOR 2019-2020**

- Recruit new members to complete the Executive Committee
- Review and update Section website to encourage interaction with and among Pediatric Clinical Pharmacology Section members
- Continue to explore outreach opportunities to disseminate pediatric clinical pharmacology knowledge and encourage junior researchers and clinicians to interact with IUPHAR and the Section members
- Continue and expand advocacy for training in Pediatric Clinical Pharmacology across both the developed and developing world
- Continue to provide support for rational medicines use in children, and to push for pediatric-specific drug development, both in the developing and the developed world
- Participate and contribute to discussions on medication costs and effectiveness from a pediatric perspective
- Contribute to international discussions on
- Contribute to the planning and organization of future pediatric clinical pharmacology events (e.g. ESDPPP 2021) and explore possibly pediatric clinical pharmacology topics to include in IUPHAR meetings.

## **3) FUNDRAISING EFFORTS**

No fundraising efforts were undertaken during the period

## **4) FUNDS IN THE BANK**

The Section has no funds on deposit

**Facundo Garcia-Bournissen, MD PhD**  
**Chairman of the Section of Paediatric Clinical Pharmacology**

---

**Facundo Garcia-Bournissen, MD PhD**  
**Clinician Researcher, Division of Paediatric Clinical Pharmacology,**  
**Associate Professor, Department of Paediatrics,**  
**Schulich School of Medicine and Dentistry**  
**Western University. London, Ontario, Canada**

**Email: [facugb1@gmail.com](mailto:facugb1@gmail.com) / [Facundo.Garcia-Bournissen@lhsc.on.ca](mailto:Facundo.Garcia-Bournissen@lhsc.on.ca)**  
**Tel (office): (519) 685-8500 ext. 52673**  
**Cell: +1-548-388-3216**